A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

(2022) Lorcan P McGarvey et al.   LANCET

Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study

(2021) Alyn Morice et al.   EUROPEAN RESPIRATORY JOURNAL

Performance of a digital signal processing algorithm for the accurate quantification of cough frequency

(2021) Jaclyn A. Smith et al.   EUROPEAN RESPIRATORY JOURNAL

The financial burden of treating patients presenting with acute and chronic cough

(2021) Surinder S. Birring et al.   CURRENT MEDICAL RESEARCH AND OPINION

Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists

(2021) Hiroyuki Kai et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough

(2021) Akio Niimi et al.   EUROPEAN RESPIRATORY JOURNAL

Chronic cough: new insights and future prospects

(2021) Alyn Morice et al.   European Respiratory Review

Minimal Clinically Important Differences for Patient-Reported Outcome Measures of Cough and Sputum in Patients with COPD

(2020) Patrícia Rebelo et al.   International Journal of Chronic Obstructive Pulmonary Disease

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

(2020) Jaclyn A Smith et al.   Lancet Respiratory Medicine

Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough

(2020) Stuart Mazzone et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Effect of Gefapixant, a P2X3 antagonist, on Cough Reflex Sensitivity: A randomised placebo-controlled study

(2019) Alyn H. Morice et al.   EUROPEAN RESPIRATORY JOURNAL

Clinical impact of gastroesophageal reflux disease in patients with subacute/chronic cough

(2019) Yoshihiro Kanemitsu et al.   ALLERGOLOGY INTERNATIONAL

ERS guidelines on the diagnosis and treatment of chronic cough in adults and children

(2019) Alyn H. Morice et al.   EUROPEAN RESPIRATORY JOURNAL

An update and systematic review on drug therapies for the treatment of refractory chronic cough

(2018) Nicole M. Ryan et al.   EXPERT OPINION ON PHARMACOTHERAPY

Drug-Induced Taste Disorders In Clinical Practice And Preclinical Safety Evaluation

(2017) Tao Wang et al.   TOXICOLOGICAL SCIENCES

The global epidemiology of chronic cough in adults: a systematic review and meta-analysis

(2015) Woo-Jung Song et al.   EUROPEAN RESPIRATORY JOURNAL

P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study

(2015) Rayid Abdulqawi et al.   LANCET

Management of chronic refractory cough

(2015) Peter G Gibson et al.   BMJ-British Medical Journal

Management of chronic refractory cough

(2015) Peter G Gibson et al.   BMJ-British Medical Journal